Comparative Pharmacology
Head-to-head clinical analysis: GABLOFEN versus METHOCARBAMOL AND ASPIRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABLOFEN versus METHOCARBAMOL AND ASPIRIN.
GABLOFEN vs METHOCARBAMOL AND ASPIRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.
None Documented
None Documented
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Methocarbamol: 1–2 hours (terminal). Aspirin: 15–20 minutes for parent drug; salicylic acid: 2–3 hours (low doses) to 15–30 hours (high doses, due to saturable metabolism). Combined product: consider aspirin's longer terminal half-life at therapeutic doses.
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Methocarbamol: Renal excretion of glucuronide and sulfate conjugates (95%) with <5% unchanged. Aspirin: Renal excretion of salicylic acid and metabolites (primarily salicyluric acid and glucuronides) with ~50% as salicylate at alkaline pH; biliary elimination <5%.
Category C
Category A/B
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant